2023-09-012024-08-312024-08-31false09653844Homerton Sports and Musculoskeletal Medicine Limited2024-10-10iso4217:GBPxbrli:pure096538442023-09-01096538442024-08-31096538442023-09-012024-08-31096538442022-09-01096538442023-08-31096538442022-09-012023-08-3109653844bus:SmallEntities2023-09-012024-08-3109653844bus:AuditExempt-NoAccountantsReport2023-09-012024-08-3109653844bus:FullAccounts2023-09-012024-08-3109653844bus:PrivateLimitedCompanyLtd2023-09-012024-08-3109653844core:WithinOneYear2024-08-3109653844core:AfterOneYear2024-08-3109653844core:WithinOneYear2023-08-3109653844core:AfterOneYear2023-08-3109653844core:ShareCapital2024-08-3109653844core:SharePremium2024-08-3109653844core:RevaluationReserve2024-08-3109653844core:OtherReservesSubtotal2024-08-3109653844core:RetainedEarningsAccumulatedLosses2024-08-3109653844core:ShareCapital2023-08-3109653844core:SharePremium2023-08-3109653844core:RevaluationReserve2023-08-3109653844core:OtherReservesSubtotal2023-08-3109653844core:RetainedEarningsAccumulatedLosses2023-08-3109653844core:LandBuildings2024-08-3109653844core:PlantMachinery2024-08-3109653844core:Vehicles2024-08-3109653844core:FurnitureFittings2024-08-3109653844core:OfficeEquipment2024-08-3109653844core:NetGoodwill2024-08-3109653844core:IntangibleAssetsOtherThanGoodwill2024-08-3109653844core:ListedExchangeTraded2024-08-3109653844core:UnlistedNon-exchangeTraded2024-08-3109653844core:LandBuildings2023-08-3109653844core:PlantMachinery2023-08-3109653844core:Vehicles2023-08-3109653844core:FurnitureFittings2023-08-3109653844core:OfficeEquipment2023-08-3109653844core:NetGoodwill2023-08-3109653844core:IntangibleAssetsOtherThanGoodwill2023-08-3109653844core:ListedExchangeTraded2023-08-3109653844core:UnlistedNon-exchangeTraded2023-08-3109653844core:LandBuildings2023-09-012024-08-3109653844core:PlantMachinery2023-09-012024-08-3109653844core:Vehicles2023-09-012024-08-3109653844core:FurnitureFittings2023-09-012024-08-3109653844core:OfficeEquipment2023-09-012024-08-3109653844core:NetGoodwill2023-09-012024-08-3109653844core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3109653844core:ListedExchangeTraded2023-09-012024-08-3109653844core:UnlistedNon-exchangeTraded2023-09-012024-08-3109653844core:MoreThanFiveYears2023-09-012024-08-3109653844core:Non-currentFinancialInstruments2024-08-3109653844core:Non-currentFinancialInstruments2023-08-3109653844dpl:CostSales2023-09-012024-08-3109653844dpl:DistributionCosts2023-09-012024-08-3109653844core:LandBuildings2023-09-012024-08-3109653844core:PlantMachinery2023-09-012024-08-3109653844core:Vehicles2023-09-012024-08-3109653844core:FurnitureFittings2023-09-012024-08-3109653844core:OfficeEquipment2023-09-012024-08-3109653844dpl:AdministrativeExpenses2023-09-012024-08-3109653844core:NetGoodwill2023-09-012024-08-3109653844core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3109653844dpl:GroupUndertakings2023-09-012024-08-3109653844dpl:ParticipatingInterests2023-09-012024-08-3109653844dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3109653844core:ListedExchangeTraded2023-09-012024-08-3109653844dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3109653844core:UnlistedNon-exchangeTraded2023-09-012024-08-3109653844dpl:CostSales2022-09-012023-08-3109653844dpl:DistributionCosts2022-09-012023-08-3109653844core:LandBuildings2022-09-012023-08-3109653844core:PlantMachinery2022-09-012023-08-3109653844core:Vehicles2022-09-012023-08-3109653844core:FurnitureFittings2022-09-012023-08-3109653844core:OfficeEquipment2022-09-012023-08-3109653844dpl:AdministrativeExpenses2022-09-012023-08-3109653844core:NetGoodwill2022-09-012023-08-3109653844core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3109653844dpl:GroupUndertakings2022-09-012023-08-3109653844dpl:ParticipatingInterests2022-09-012023-08-3109653844dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3109653844core:ListedExchangeTraded2022-09-012023-08-3109653844dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3109653844core:UnlistedNon-exchangeTraded2022-09-012023-08-3109653844core:NetGoodwill2024-08-3109653844core:IntangibleAssetsOtherThanGoodwill2024-08-3109653844core:LandBuildings2024-08-3109653844core:PlantMachinery2024-08-3109653844core:Vehicles2024-08-3109653844core:FurnitureFittings2024-08-3109653844core:OfficeEquipment2024-08-3109653844core:AfterOneYear2024-08-3109653844core:WithinOneYear2024-08-3109653844core:ListedExchangeTraded2024-08-3109653844core:UnlistedNon-exchangeTraded2024-08-3109653844core:ShareCapital2024-08-3109653844core:SharePremium2024-08-3109653844core:RevaluationReserve2024-08-3109653844core:OtherReservesSubtotal2024-08-3109653844core:RetainedEarningsAccumulatedLosses2024-08-3109653844core:NetGoodwill2023-08-3109653844core:IntangibleAssetsOtherThanGoodwill2023-08-3109653844core:LandBuildings2023-08-3109653844core:PlantMachinery2023-08-3109653844core:Vehicles2023-08-3109653844core:FurnitureFittings2023-08-3109653844core:OfficeEquipment2023-08-3109653844core:AfterOneYear2023-08-3109653844core:WithinOneYear2023-08-3109653844core:ListedExchangeTraded2023-08-3109653844core:UnlistedNon-exchangeTraded2023-08-3109653844core:ShareCapital2023-08-3109653844core:SharePremium2023-08-3109653844core:RevaluationReserve2023-08-3109653844core:OtherReservesSubtotal2023-08-3109653844core:RetainedEarningsAccumulatedLosses2023-08-3109653844core:NetGoodwill2022-09-0109653844core:IntangibleAssetsOtherThanGoodwill2022-09-0109653844core:LandBuildings2022-09-0109653844core:PlantMachinery2022-09-0109653844core:Vehicles2022-09-0109653844core:FurnitureFittings2022-09-0109653844core:OfficeEquipment2022-09-0109653844core:AfterOneYear2022-09-0109653844core:WithinOneYear2022-09-0109653844core:ListedExchangeTraded2022-09-0109653844core:UnlistedNon-exchangeTraded2022-09-0109653844core:ShareCapital2022-09-0109653844core:SharePremium2022-09-0109653844core:RevaluationReserve2022-09-0109653844core:OtherReservesSubtotal2022-09-0109653844core:RetainedEarningsAccumulatedLosses2022-09-0109653844core:AfterOneYear2023-09-012024-08-3109653844core:WithinOneYear2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:CostValuation2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3109653844core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3109653844core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3109653844core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3109653844core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3109653844core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3109653844core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3109653844core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3109653844core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3109653844core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3109653844core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3109653844core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3109653844core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3109653844core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3109653844core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3109653844core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3109653844core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3109653844core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3109653844core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3109653844bus:Director12023-09-012024-08-3109653844bus:Director22023-09-012024-08-31

Homerton Sports and Musculoskeletal Medicine Limited

Registered Number
09653844
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2024

Homerton Sports and Musculoskeletal Medicine Limited
Company Information
for the year from 1 September 2023 to 31 August 2024

Directors

Peter Resteghini
Carol Ann Resteghini

Registered Address

42 High Street, Wanstead
London
E11 2RJ

Registered Number

09653844 (England and Wales)
Homerton Sports and Musculoskeletal Medicine Limited
Balance Sheet as at
31 August 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets36,0506,600
6,0506,600
Current assets
Debtors4105105
Cash at bank and on hand633,150495,974
633,255496,079
Creditors amounts falling due within one year5(77,166)(47,955)
Net current assets (liabilities)556,089448,124
Total assets less current liabilities562,139454,724
Net assets562,139454,724
Capital and reserves
Called up share capital500500
Profit and loss account561,639454,224
Shareholders' funds562,139454,724
The financial statements were approved and authorised for issue by the Board of Directors on 10 October 2024, and are signed on its behalf by:
Peter Resteghini
Director
Registered Company No. 09653844
Homerton Sports and Musculoskeletal Medicine Limited
Notes to the Financial Statements
for the year ended 31 August 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Turnover policy
Turnover represents the net invoiced value of services rendered.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. Goodwill, being the amount paid in connection with the acquisition of a business in 2015, is being amortised evenly over its estimated useful life of twenty years.
2.Average number of employees

20242023
Average number of employees during the year11
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 September 2311,00011,000
At 31 August 2411,00011,000
Amortisation and impairment
At 01 September 234,4004,400
Charge for year550550
At 31 August 244,9504,950
Net book value
At 31 August 246,0506,050
At 31 August 236,6006,600
4.Debtors: amounts due within one year

2024

2023

££
Prepayments and accrued income105105
Total105105
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
5.Creditors: amounts due within one year

2024

2023

££
Amounts owed to related parties41,86227,765
Taxation and social security35,30420,190
Total77,16647,955
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.